Investigating the effect of metformin on the activity of systemic lupus erythematosus
Phase 2
- Conditions
- Systemic lupus erythematosus.Systemic lupus erythematosus, unspecifiedM32.9
- Registration Number
- IRCT20220817055730N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
suffering from Systemic lupus erythematosus disease
Age above 18 years
Exclusion Criteria
Kidneys involvement
Central Nervous System involvement
Heart failure
Hepatic failure
pregnancy
Breast feeding
Alcohol consumption
Metformin use due to Diabetes mellitus
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does metformin target in systemic lupus erythematosus (SLE) pathogenesis?
How does metformin compare to standard-of-care therapies like hydroxychloroquine in SLE disease activity reduction?
Which biomarkers correlate with metformin response in SLE patients with M32.9 unspecified classification?
What adverse events are associated with metformin use in autoimmune disease trials and how are they managed?
Are there combination therapies involving metformin and JAK inhibitors showing promise in SLE treatment?